|March 27, 2014|
|07:03 EDT||BLUE||Bluebird Bio announces first patient transplanted in Phase 1/2 Northstar study|
bluebird bio announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 Northstar Study -- HGB-204 -- in the United States and has undergone infusion with bluebird bio’s LentiGlobin drug product in an autologous hematopoietic stem cell transplantation. The phase 1/2 study is designed to evaluate the feasibility, safety and efficacy of LentiGlobin drug product in the treatment of subjects with beta-thalassemia major. The study is designed to enroll up to fifteen subjects. Subjects will be evaluated for safety and efficacy post-transplant.
News For BLUE From The Last 14 Days
|October 8, 2015|
|06:32 EDT||BLUE||Piper Jaffray explains why drug prices are justifiable|
Piper Jaffray's team of Biopharma analysts, led by Joshua Schimmer, explain this morning in research note to investors why they believe drug prices are justifiable. The "fairly lopsided" drug-pricing discussion "noise" has created attractive entry points for stocks in the sector, the analysts argue. They say that after adjusting for actual inflation, the growth of drug prices "does not seem particularly concerning." The current dialogue on the topic under-emphasizes the need to provide "extremely attractive incentives" for companies to embark on the "highly risky, capital-intensive, long-development cycle drug development path which is needed to bring new cures for important diseases," the analysts contend. Schimmer's top picks are Alexion (ALXN), Celgene (CELG) and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC) and Ignyta (RXDX) in the small-cap sector.
|October 6, 2015|
|13:32 EDT||BLUE||Biotechs plummet with TPP seen as industry negative |
Biotechs are falling intraday after reports that the Trans-Pacific Partnership, or TPP, has language that the exclusivity period for bioligics, or drugs derived from a biological sources, would be eight years, less than the twelve years it is currently in the United States. WHAT'S NOTABLE: In the U.S., biologics are protected from competition by follow-on products for twelve years from the time they are first granted marketing approval by the U.S. Food and Drug Administration, a protection that is distinct from patent protection. Recent reports on the TPP suggest that the protection will last five years with an additional safety monitoring period of up to three years before a biosimilar can be registered, which would effectively be an eight year exclusivity period. ANALYST REACTION: Piper Jaffray analyst Joshua Schimmer, however, said the development is a "step forward," especially since it does not overrule the 12 years' exclusivity for the drugs in the U.S. While the sector asked for twelve years' exclusivity to match the U.S., eight years is a "reasonable compromise," the analyst argued. His top picks were Alexion (ALXN), Celgene (CELG), and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC), and Ignyta (RXDX) in the small-cap sector. Further, Schimmer stated that more names look "increasingly compelling" amid the selloff. NOTABLE DECLINERS: Alexion is lower by 2.53%, Celgene is down 4.32%, Amgen is declining 1.91%, Biogen (BIIB) is down 3.4%, and Gilead Sciences (GILD) is falling 2.22%. STOCKS TO WATCH: Other publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
|12:06 EDT||BLUE||Piper's Schimmer sees opportunity in Biopharma on TPP-related selloff|
Piper Jaffray analyst Joshua Schimmer says Biopharma stocks are selling off with some spinning the eight years of exclusivity for biologics as part of the Trans Pacific Partnership as a negative for the industry. The development is a "step forward," especially since it does not over-rule the 12 years' exclusivity for the drugs in the U.S., Schimmer tells investors in an intraday research note. While the sector asked for 12 years' exclusivity to match the U.S., eight years is a "reasonable compromise," the analyst argues. His top picks remain Alexion (ALXN), Celgene (CELG) and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC) and Ignyta (RXDX) in the small-cap sector. Further, Schimmer writes that more names look "increasingly compelling" amid the selloff.
|October 5, 2015|
|10:19 EDT||BLUE||Spark trial success a positive for gene therapy sector, says Piper Jaffray|
Piper Jaffray analyst Joshua Schimmer said he views the news that Spark Therapeutics (ONCE) "highly anticipated" SPK-RPE65 Phase 3 gene therapy study for congenital blindness met its primary endpoint as a positive for the ophthalmology gene therapy field as well as the broader gene therapy sector. Schimmer added that Applied Genetic Technologies' (AGTC) early clinical data in the second half of this year will be a further test of the ophthalmology gene therapy platform. The analyst noted that other companies with gene therapy programs include Avalanche (AAVL), Biogen (BIIB), bluebird bio (BLUE), BioMarin (BMRN), Cellectis (CLLS), Medgenics (MDGN), uniQure (QURE), Pfizer (PFE), Regeneron (REGN) and Sangamo (SGMO).
|10:00 EDT||BLUE||On The Fly: Analyst Upgrade Summary|
Today's noteworthy upgrades include: ADT Corp. (ADT) upgraded to Equal Weight from Underweight at Barclays... Allegheny Technologies (ATI) upgraded to Buy from Hold at Deutsche Bank... Amicus (FOLD) upgraded to Buy from Neutral at Chardan... ArcelorMittal (MT) upgraded to Buy from Sell at Citi... AutoZone (AZO) upgraded at Oppenheimer... BE Aerospace (BEAV) upgraded to Buy from Hold at Gabelli... Boston Scientific (BSX) upgraded to Strong Buy from Outperform at Raymond James... C1 Financial (BNK) upgraded to Buy from Hold at Sandler O'Neill... CONSOL (CNX) upgraded to Hold from Sell at Deutsche Bank... Discover (DFS) upgraded to Outperform from Market Perform at Bernstein... Dr Pepper Snapple (DPS) upgraded to Buy from Hold at Evercore ISI... International Game (IGT) upgraded on valuation at Sterne Agee CRT... Juniper (JNPR) upgraded to Buy from Hold at Stifel... Keryx (KERX) upgraded to Equal Weight from Underweight at Morgan Stanley... Knowles (KN) upgraded to Overweight from Equal Weight at Stephens... LaSalle Hotel (LHO) upgraded to Buy from Hold at Evercore ISI... Lazard (LAZ) upgraded to Positive from Neutral at Susquehanna... Nucor (NUE) upgraded to Buy from Hold at Deutsche Bank... OUTFRONT Media (OUT) upgraded to Buy from Neutral at Goldman... Park Sterling Bank (PSTB) upgraded to Buy from Hold at Sandler O'Neill... Phoenix Companies (PNX) upgraded to Neutral from Underweight at JPMorgan... SBA Communications (SBAC) upgraded to Outperform from Neutral at Macquarie... Snap-On (SNA) upgraded to Buy from Neutral at Longbow... Swift Transport (SWFT) upgraded to Buy from Hold at Evercore ISI... Team (TISI) upgraded to Buy from Hold at Johnson Rice... Teck Resources (TCK) upgraded to Outperformer from Sector Performer at CIBC... Toll Brothers (TOL) upgraded to Positive from Neutral at Susquehanna... Twitter (TWTR) upgraded to Buy from Neutral at Axiom... UniCredit (UNCFF) upgraded to Sector Perform from Underperform at RBC Capital... Wynn Resorts (WYNN) upgraded to Market Perform from Underperform at Telsey Advisory... bluebird bio (BLUE) upgraded to Overweight from Equal Weight at Morgan Stanley.
|09:12 EDT||BLUE||On The Fly: Pre-market Movers |
HIGHER: Spark Therapeutics (ONCE), up 45.7% after SPK-RPE65 trial met its primary endpoint... Amicus Therapeutics (FOLD), up 12.1% after being upgraded to Buy from Neutral at Chardan... bluebird bio (BLUE), up 5.3% after being upgraded to Overweight from Equal Weight at Morgan Stanley... Sunedison (SUNE), up 3.8% after announcing initiatives to optimize its business operations... General Electric (GE), up 3% after Trian disclosed a $2.5B stake in GE. LOWER: FireEye (FEYE), down 3.5% after being downgraded to Neutral from Overweight at Piper Jaffray... Applied Materials (AMAT), down 1.9% after being downgraded to Underperform from Sector Perform at RBC Capital... Cal-Maine Foods (CALM), down 2.1% after being downgraded to Hold from Buy at BB&T.
|06:28 EDT||BLUE||bluebird bio upgraded to Overweight from Equal Weight at Morgan Stanley|
Morgan Stanley analyst Matthew Harrison upgraded bluebird to Overweight with a $143 price target. Harrison said valuation now heavily reflects any potential competition in sickle cell disease and expects data at ASH in early December to be a key near-term catalyst. The analyst expects the data to show significant increases in hemoglobin similar to the first sickle cell disease patient.
|October 1, 2015|
|07:31 EDT||BLUE||Leerink to hold a roundtable|
Subscribe for More Information
|September 29, 2015|
|08:33 EDT||BLUE||Alexandria Real Estate announces bluebird bio executed lease|
Alexandria Real Estate (ARE) Equities announced that bluebird bio (BLUE) executed a 10-year lease for approximately 253,000 rentable square feet at 60 Binney Street at the Alexandria Center at Kendall Square campus. The lease encompasses the entire 60 Binney Street building with the exception of a ground-floor retail suite. With the relocation of its headquarters to 60 Binney Street, bluebird bio, a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, will be expanding its presence in Cambridge to support the company's continued growth. The 60 Binney Street project, which is targeting LEED Gold Certification, is expected to be delivered in late 2016.
|September 25, 2015|
|11:35 EDT||BLUE||bluebird bio management to meet with Maxim|
5:30 pm Cocktails, followed by 6pm Group dinner with management will be held in New York on September 30 hosted by Maxim.